Cytokeratin19 (KRT19) is widely used as a biomarker for the detection of disseminated tumors. Using an LC-MS/MS proteomics approach, we found that KRT19 was upregulated in HER2-overexpressing cells and tissues. KRT19 expression was induced by HER2-downstream ERK at the transcriptional level. Another HER2-downstream kinase, Akt, was found to phosphorylate KRT19 on Ser35 and induce membrane translocation of KRT19 and remodeling of KRT19 from filamentous to granulous form. KRT19 phosphorylated by Akt could bind HER2 on the plasma membrane and stabilized HER2 via inhibition of proteasome-mediated degradation of HER2. Silencing of KRT19 by shRNA resulted in increased ubiquitination and destabilization of HER2. Moreover, treatment of KRT19 antibody resulted in downregulation of HER2 and reduced cell viability. These data provide a new rationale for targeting HER2-positive breast cancers.
Overexpression of HER2 is associated with aggressive tumors and poor clinical prognosis. 1 The mechanism(s) by which HER2 overexpression elicits more severe tumor phenotypes remains largely obscure; however, it has been reported that HER2 is a preferred binding partner for other HER family receptors 2 and intracellular signaling from HER2-containing heterodimers is more robust. 3 The HER2 receptor activates several signal pathways including the phosphatidylinositol-3-kinase-PKB/Akt pathway and the extracellular signal-regulated protein kinase (ERK) pathway. 4, 5 Akt regulates cellular survival and metabolism via phosphorylation of many downstream effectors. 6 Numerous substrates of Akt with the recognition motif of RXRXX(S/T), were reported. 7 Another HER2-downstream signaling molecule, ERK is found in the cytosol of quiescent cells, but translocates to the nucleus upon activation by upstream kinases. 8 Once in the nucleus, ERK can phosphorylate and regulate transcription factors, including Elk-1, 9 c-fos, 10 and Sp1.
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Cytokeratins (KRTs) are intermediate filaments found in epithelial tissue. 12 KRTs are dynamically regulated and interact with a range of cellular proteins including kinases, receptors, adaptors, and other types of effector molecules to regulate cellular responses to apoptosis, cell migration, and growth. 13 KRT19 is the smallest (40 kDa) known intermediate filament protein 14 and differs from other KRTs in that it has a short tail domain. 15 KRT19 is used as a marker for RT-PCR-mediated detection of tumor cells disseminated in lymph nodes, peripheral blood, and bone marrow of breast cancer patients, and its positivity could be considered as a prognostic indicator. [16] [17] [18] Using a proteomics approach, two-dimensional digest-LC-MS/MS, 19 we confirmed that KRT19 expression is upregulated in HER2-overexpressing cells. To determine the signaling pathway responsible for upregulation of KRT19, we investigated the roles of HER2-downstream molecules such as ERK and Akt in KRT19 expression, as well as its subcellular distribution. Furthermore, we also examined the role of KRT19 in stabilizing HER2 on the cell membrane and the effect of KRT19 antibody on proliferation of HER2-positive cancer cells.
Results
HER2 expression is coupled with KRT19 expression. We found that several KRTs were upregulated in MCF-7 HER2 cells as compared with control cells by LC-MS/MS proteomics (Supplementary Table 1 ). We confirmed the expression of KRTs by western blot analyses ( Figure 1a ). KRT19 was also upregulated both at the transcriptional and translational level in high-HER2-expressing breast cancer cells (Figure 1b) , suggesting that HER2 expression is coupled with KRT19 expression. We confirmed these results in vivo using a mouse model that overexpresses HER2/neu. Both immunohistochemistry and RT-PCR approaches revealed that KRT19 was upregulated in the mammary glands of MMTV-HER2/neu mice as compared with their wild-type (WT) littermates (Figure 1c ). HER2 levels in human breast tumor tissue were also strongly correlated with KRT19 levels (Figure 1d ). To exclude the possibility that HER2 expression increases the solubility of KRT19 rather than upregulating levels of KRT19 protein, both soluble fraction and insoluble pellets were tested for KRT19 expression (Supplementary Figure 1) . These results indicate that HER2 expression is coupled with increased KRT19 in both detergent-soluble and -insoluble fractions.
Expression of KRT19 is modulated by HER2-downstream ERK signaling at the level of transcription. Using various inhibitors of protein kinases, we investigated whether any of the kinase activity is responsible for the upregulation of KRT19. RT-PCR analyses revealed that blockade of HER2 by ZD1839 or MEK by U0126 could decrease KRT19 mRNA in a dose-dependent manner (Figures 2a and c) . The other inhibitors failed to exert any effect on KRT19 mRNA, suggesting that upregulation of KRT19 is mediated specifically by the tyrosine kinase activity of HER2 and its downstream MEK/ERK signaling.
To determine whether HER2-induced upregulation of KRT19 mRNA was mediated by increased transcriptional activity of the KRT19 promoter, reporter assays were performed (Figure 2b, left panel) . We used the pK19-1970-LucReporter containing the promoter region of KRT19. 20 The transcriptional activity of the KRT19 promoter in MCF-7 HER2 cells was significantly higher than control cells. We obtained similar results in 293T cells co-transfected with HER2 and MEK or ERK, but not by other kinases (Figure 2b , right panel).
As depicted in Figures 2d and e, only ZD1839 and U0126 could downregulate protein levels of KRT19 in a dosedependent fashion. These results indicate that HER2 increased KRT19 expression in ectopic HER2-overexpressing cells, as well as cells expressing endogenous HER2. The expression levels of other KRTs, which were also upregulated in MCF-7 HER2 cells (Figure 1a) , were not effectively inhibited by either Figure 1 Expression of KRT19 is strongly correlated with HER2 levels in cultured breast cancer cells, transgenic mouse tissues, and patient tumor samples (a) Total cell lysates were prepared from MCF-7 vec and MCF-7 HER2 cells and subjected to the indicated western blot analyses with HER2, KRT9, KRT1/10 or KRT18 antibodies. Actin was used to verify equal loading. (b) Total cell lysates were prepared from human breast cancer cell lines. The samples were resolved by SDS-PAGE and subjected to western blot analyses with HER2 or KRT19 antibodies. RNA was extracted from human breast cancer cell lines and the samples were subsequently analyzed by RT-PCR using KRT19-specific primers. Actin primers were used as loading controls. (c) Paraffin-embedded sections from the #4 mammary gland tissues of MMTV-HER2/neu transgenic mice and wildtype littermates were subjected to immunohistochemistry with a KRT19 antibody. MMTV-HER2/neu transgenic mice and wild-type littermates (16 weeks, n = 4 each) #4 mammary gland tissues were analyzed by RT-PCR using mouse KRT19 primers, and western blot analyses with HER2 or KRT19 antibodies. Akt-mediated phosphorylation of KRT19 results in remodeling of KRT19 from filamentous to granulous forms. By using Scansite (http://scansite.mit.edu), we found two possible Akt phosphorylation sites in KRT19 (Figure 3a) . Although the optimal recognition motif is RXRXX(S/T), several reports indicate that R at − 5 position is not critically required for Akt substrates, [21] [22] [23] [24] which is interesting as the putative Akt phosphorylation sites on KRT19, S10 and S35, both lack R at − 5. To determine whether one of these residues is indeed phosphorylated by Akt, WT or alaninesubstitution KRT19 mutants were transiently co-transfected with constitutively active Akt1 into 293T cells, and the cell lysates were immunoprecipitated with a KRT19 antibody. The resulting immunoprecipitate complexes were then probed with an Akt substrate antibody, which can recognize phosphorylated RXX(S/T) residues. 25 Immunoprecipitates containing either the KRT19-WT or KRT19-S10A were recognized by the Akt substrate antibody, whereas KRT19-S35A and KRT19-S10A S35A were not immunoreactive against the antibody, suggesting that S35 of KRT19 may be the putative Akt phosphorylation site (Figure 3a) . In MCF-7 HER2 cells that have much higher Akt activity than MCF-7 vec cells due to HER2 overexpression (Figure 2d ), anti-KRT19 immunoprecipitates exhibited stronger immunoreactivity toward the Akt substrate antibody (Figure 3a) . To exclude the possibility that other Akt-downstream protein kinase might be involved, in vitro kinase assays were performed (Figure 3b ). Our results showed that Akt could effectively phosphorylate KRT19 at S35, but not S10. Furthermore, in cells co-transfected with constitutively active Akt, only KRT19-WT and KRT19-S10A could incorporate [32P]-orthophosphate, confirming that S35 in KRT19 is an Akt phosphorylation site (Figure 3c ). Studies using kinase inhibitors in HER2-overexpressing cells (Figure 3d ) revealed that inhibition of Akt could inhibit KRT19 phosphorylation.
It appeared that KRT19 subcellular localization and appearance were vastly different between MCF-7 vec and MCF-7 HER2 cells (Figure 3e ). In MCF-7 vec cells, KRT19 exhibited a filamentous shape, whereas KRT19 in MCF-7 HER2 cells have a granulated morphology. To determine whether phosphorylation of S35 is responsible for the modification of KRT19, we co-transfected KRT19 with constitutively active Akt (HA-Akt1-CA), kinase-dead Akt (HA-Akt1-KD) or other kinases into 293T cells. In cells co-transfected with KRT19-WT or KRT19-S10A with HA-Akt1-CA, HER2-WT or HER2-CA, immunostaining patterns of KRT19 were similar to that of KRT19 in MCF-7 HER2 cells, whereby KRT19 molecules in the cytosol have a granulated appearance (Supplementary Figure 2) . In contrast, the staining patterns of KRT19 in cells co-transfected with other kinase constructs and KRT19-S35A or KRT19-S10A S35A were very similar to MCF-7 vec cells, whereby KRT19 appeared as a long filamentous fiber (Supplementary Figure 2) . Quantification of the results in Figure 3e and Supplementary Figure 2 is shown in Figures 3f and g . These results indicated that Akt-mediated phosphorylation of KRT19 on S35 was responsible for the KRT19 subcellular shape.
Physical association of HER2 and KRT19 in the plasma membrane. We performed immunofluorescence staining using HER2 and KRT19 antibodies. As depicted in optically sectioned images (Supplementary Figure 3a) , a significant portion of KRT19 was identified in the cell periphery. Membrane KRT19 appeared to be colocalized with HER2 in the cell membrane. As it was previously documented that KRTs are mostly cytosolic, we reconfirmed membrane localization of KRT19 by other methods including subcellular fractionation, cell-surface immunofluorescence labeling and cell-surface protein biotinylation assay. Membrane fractions of MCF-7 HER2 cells contained KRT19, whereas that from MCF-7 vec cells did not (Figure 4a) . Similarly, BT-474 cells with high HER2 also contained KRT19 in the membrane. Aquaporin 4 was a membrane fraction marker. Cell surface immunofluorescence labeling confirmed that immunoreactivity toward KRT19 antibody was found in the membranes of MCF-7 HER2 and BT-474 cells, but not in membranes of MCF-7 vec cells (Figure 4c ). The cell-surface protein biotinylation assay also confirmed that membrane KRT19 was upregulated in MCF-7 HER2 cells as compared with vec cells (Figure 4d , left panels, lane 1 versus 3). After serum starvation, membrane KRT19 was decreased (lanes 5 and 6) and treatment with insulin-like growth factor could rescue the levels (lanes 7 and 8). Akt inhibitor could also decrease membrane KRT19 (lanes 9 and 10). Essentially the same results were observed in BT-474 and SKBR-3 cells (Figure 4d , right panels). The HER2 was used as a positive control for membrane protein. Cytosolic ERK was not detected by both cell-surface-labeling experiments (Figures 4c and d, right panels). We analyzed the amino-acid sequence of KRT19 by the membrane protein explorer program (http://blanco.biomol.uci.edu/mpex/). The prediction results indicated that KRT19 may contain some membraneassociated β-barrel motifs, indicating that some domain of KRT19 might be associated with the plasma membrane.
We next evaluated the possibility of a physical association of KRT19 with HER2. HER2 and KRT19 were co-immunoprecipitated in HER2-overexpressing cells ( Figure 4b ). When KRT19-WT was co-transfected with fulllength HER2 (HER2-FL-myc) or truncated mutant constructs (intracellular, HER2-ICD-myc or extracellular domain, HER2-ECD-myc), we observed association between KRT19 and extracellular domain of HER2 (Figure 4e ). We next asked whether membrane localization of KRT19 requires the presence of HER2. When HA-Akt1-CA was co-transfected with HER2, we observed membrane localization of KRT19-WT and KRT19-S10A (Supplementary Figure 3b , left panels). However, when the Akt activity was blocked by HA-Akt1-KD, we could not detect any membrane-associated KRT19-WT and KRT19-S10A. Indeed, both KRT19-S35A and KRT19-S10A S35A failed to exhibit membrane localization under any conditions, suggesting that both Akt-mediated phosphorylation of KRT19 on S35 and the presence of HER2 are required for the membrane localization of KRT19. These data coincide with results in Figure 4d where membrane KRT19 was decreased by the Akt inhibitor. Furthermore, it appeared that the kinase activity of HER2 was not directly required for the membrane localization of KRT19, as HER2-KD-expressing cells could also induce membrane localization of KRT19 as Figure 3 KRT19 is phosphorylated by HER2 downstream of Akt at Ser35, resulting in remodeling of KRT19 from filamentous to granulous form (a) Total cell lysates were incubated with KRT19 antibody overnight. Immunoprecipitates were subjected to western blot analysis with Akt substrate antibody or KRT19 antibody. (b) GST-KRT19 was prepared as described. HA-Akt precipitates were used as a kinase source for in vitro kinase assays. After the reaction, the samples were subjected to SDS-PAGE and subsequent autoradiography. Equal loading of KRT19 per reaction was confirmed by Coomassie brilliant blue staining. (c) In vivo phosphorylation of KRT19 was assessed by labeling 293T cells transfected with KRT19 with 32P-orthophosphate. 32P-labeled KRT19 was precipitated with KRT19 antibody and analyzed by autoradiography. To normalize for transfection sufficiency, precipitates were subjected to KRT19 immunoblotting. KRT19 stabilizes HER2 on cell membranes. We next asked whether HER2 and Akt-induced membrane-localized KRT19 had any effect on HER2 in the plasma membrane. Cycloheximide-decay assays showed that co-expression of KRT19-WT and KRT19-S10A significantly increased the stability of HER2-WT, whereas KRT19-S35A and KRT19-S10A S35A had no effect (Figure 5a, left panel) . Similarly, HA-Akt1-CA effectively upregulated the stability of HER2-KD when co-transfected with KRT19-WT or KRT19-S10A (Figure 5a , middle panel). However, when HA-Akt1-KD was co-transfected, none of the KRT19 constructs were able to increase the stability of HER2-KD (Figure 5a, right panel) . These data suggest that upon phosphorylation by Akt on S35, KRT19 localizes to the cell membrane where it binds to and stabilizes HER2 in a HER2 kinase-activity-independent fashion.
To further confirm the effect of KRT19 on HER2 protein stability, KRT19 knockdown cell lines were generated. KRT19 shRNA-expressing cells exhibited a clear KRT19 knockdown phenotype as compared with control shRNA-expressing cells (Figure 5b ). Knockdown of KRT19 impaired the stability of HER2 (Figure 5b , lanes 1-4 in all panels). To check whether HER2 stability conferred by presence of KRT19 was also dependent on Akt activity, an Akt inhibitor was co-treated with cycloheximide ( Figure 5b , lanes 9-12 in all panels). When Akt activity was blocked, the decay slopes of HER2 were similar between control and KRT19 shRNA cells. Comparison of HER2 protein stability between control cells treated with cycloheximide alone or cycloheximide and the Akt inhibitor ( Figure 5b , lanes 1-4 versus lanes 9-12 in control shRNA panels) revealed that there was a significant decrease in HER2 stability in cells treated with both the Akt inhibitor and cycloheximide compared with cells treated with cycloheximide alone. However, when the samples from KRT19 shRNA cells were compared, there were no significant differences in HER2 stability between cells treated with both the Akt inhibitor and cycloheximide compared with cells treated with cycloheximide alone (Figure 5b , lanes 1-4 versus lanes 9-12 in KRT19 shRNA panels). These data indicate that KRT19 regulates HER2 stability in an Akt-activity-dependent manner. We also checked whether inhibition of Akt activity alone could impair HER2 levels. When Akt inhibitor-treated control shRNA cells and Akt inhibitor-treated KRT19 shRNA cells were compared When the cell lysates were treated with alkaline phosphatase to dephosphoryate phosphoproteins, we observed that HER2 levels were downregulated in cells expressing KRT19 (Figure 5c ). However, in cells not expressing KRT19, treatment with alkaline phosphatase did not significantly affect HER2 protein levels. The results may suggest that the phosphorylation of KRT19 is critical in maintaining HER2 protein stability, because cell lines devoid of KRT19 do not exhibit significant differences in HER2 protein levels with or without treatment with phosphatases. Finally, to rule out the possibility of KRT19 modulating HER2 protein by inducing changes in HER2 mRNA, RT-PCR experiments were employed (Figure 5d ). HER2 mRNA levels were similar both in control shRNA and KRT19 shRNA cells.
KRT19 inhibits ubiquitin-mediated degradation of HER2. We were next interested in determining whether KRT19 increases the stability of HER2 by modulation of a HER2-protein-degradation mechanism. Treatment with MG132, a 26S proteasome inhibitor, resulted in increased HER2 protein level, as well as increased ubiquitination of HER2 (Figures 6a and b) . Increased ubiquitination of HER2 was more evident in KRT19 shRNA cells (Figure 6a ubiquitination of HER2 is more actively processed in KRT19-silenced cells. To further determine whether the phosphorylation status of KRT19 is responsible for the ubiquitination of HER2, KRT19 point mutants were co-transfected along with various combinations of kinases (Figure 6c ). Cells cotransfected with HER2-WT and KRT19-S35A, KRT19-S10A S35A or empty vector exhibited intensive levels of HER2 ubiquitination upon MG132 treatment (lanes 1, 4, 5) . When HER2-KD was co-transfected with HA-Akt1-CA and KRT19 constructs, we observed that the pattern of HER2 ubiquitination was highly similar to that observed in HER2-WTexpressing cells (lanes 2-5 versus 6-9), suggesting that Akt activity and the S35 residue of KRT19 are absolute requirements for preventing hyper-ubiquitination of HER2. In cells co-transfected HER2-KD, HA-Akt1-KD and KRT19, all of the samples exhibited intensive ubiquitination of HER2, confirming that Akt kinase activity is necessary to prevent hyper-ubiquitination of HER2. Accordingly, KRT19 was shown to be co-immunoprecipitated with HER2 in samples exhibiting basal levels of HER2 ubiquitination (lanes 2, 3, 6, 7). (Figure 6f ). We performed xenograft experiments to determine the efficiency of KRT19 antibody in vivo (Figure 6g and Supplementary Figure 4) . The mice were treated with KRT19 antibody or Trastzumab for 3 weeks. We found that treatment with KRT19 antibody inhibited the in vivo tumor formation. Complete tumor dissipation was observed in all mice treated with KRT19 antibody or Trastzumab at day 24. Administration of KRT19 antibody was non-toxic, as analyzed by animal survival and weight-loss analyses. These results indicate KRT19 may be a novel therapeutic target in HER2-expressing cancer cells.
Discussion
We showed here that (1) expression of KRT19 was upregulated by the HER2-downstream MEK/ERK pathway, (2) HER2-downstream Akt could phosphorylate KRT19 at S35 and induce localization of KRT19 to the membrane, (3) membrane-localized KRT19 can bind and stabilize HER2 by inhibition of HER2 ubiquitination and (4) KRT19 antibody treatment could interfere with HER2 signaling and reduce proliferation of HER2-positive cells both in vitro and in vivo. A previous study showed that KRT19 was increased in HER2-positive tumors. 26 They concluded that KRT19 might be responsible for driving the phenotypes of HER2-positive tumors; however, they did not provide any mechanistic relationship between HER2 and KRT19.
It was previously shown that the Sp1-binding site at − 62 is a critical element for KRT19 promoter activity. 20 In hamster fibroblasts, vascular endothelial growth factor (VEGF) expression is under control of ERK, 27 which targets Sp1 and promotes its phosphorylation. 11 The phosphorylated form of Sp1, in turn, drives transcription from the VEGF promoter, which contains two binding sites for this transcription factor. Sp1 phosphorylation is also achieved by ERK activity. 28 With these findings, we speculated that HER2/MEK/ERK-driven upregulation of KRT19 transcripts might be mediated by the ERK-dependent activation of Sp1. However, we could not completely rule out the possibility of KRT19 regulation at posttranscriptional levels, as the changes in KRT19 protein level by HER2 is more marked than KRT19 mRNA levels.
KRTs are unique as they are regulated by phosphorylation. 29 Site-specific phosphorylation occurs during mitosis, where KRTs undergo hyperphosphorylation. 29 Phosphorylation of KRTs occurs in a particular type of cell to regulate a specific cell function. 29 In a previous study, KRT19 S35 was reported to be the major phosphorylation site; the same study also showed that a KRT19-S35A mutant exhibits a filament assembly defect. 30 Our results also indicated that phosphorylation of KRT19 on the S35 residue is an absolute requirement for the transition from a filamentous to a granulous shape. A recent report also showed that Akt2 could induce reorganization of cytoplasmic intermediate filaments including KRTs. 31 Furthermore, inhibition of tyrosine phosphatase resulted in the formation of KRT13 and KRT5 granules. 32 Upregulation of p38MAPK activity induced KRT granule formation, whereas pharmacological inhibition of p38MAPK resulted in stabilization of KRT filament networks. 33 Phosphorylation of residues in the head domain of KRTs were required for the assembly of KRTs. 33 When hyperphosphorylation status were induced by okadaic acid, KRT18-WT-transfected cells exhibited disassembly of the filament network into short filaments and aggregates of dots, whereas KRT18-S52A-transfected cells exhibited a normal morphology. 34 On the basis of the findings, we speculated that phosphorylation of S35 could lead to a configuration of KRT19, which might be responsible for the filament disassembly.
Recently, it was reported that full-length KRT19 is released by tumor cells. 35 The authors showed that KRT19 release is an active process, not a consequence of cell death. As KRT19 lacks both a secretory signal sequence and transmembrane sequence, the authors speculated that the KRT19 release might be mediated by release through exosomes or other unknown transport pathways. They also showed that both MUC1 and KRT19 are co-expressed in the cell periphery, KRT19 staining pattern of which was quite similar to our results shown in Figure 4 . On the basis of this previous assumption, we further hypothesized that the translocation mechanism of KRT19 results in its movement to the plasma membrane of HER2-expressing cells (illustrated in Figure 6h) . Upon induction by a HER2-downstream MEK/ERK pathway, KRT19 is phosphorylated by Akt on S35. KRT19 phosphorylated on S35 then disassembled into a granulous shape in preparation for transport to the cell membrane or extracellular space, possibly by packaging into exosomes. During its travel to the cell periphery, some KRT19 encounter and bind HER2 inside the trafficking vesicle or near the plasma membrane. Indeed, we also observed that HER2 could increase the release of KRT19 to the culture medium, and treatment with MEK, Akt inhibitors or exosome inhibitor 5-(N,N-dimethyl) amiloride hydrochloride could block KRT19 release as well as its binding to HER2 (Supplementary Figure 5) . After binding to HER2, KRT19 stabilizes HER2 via inhibition of ubiquitination and subsequent proteosomal degradation of HER2, creating a positive-feedback loop encircling HER2-induced KRT19 expression and KRT19-induced stabilization of HER2. Although elucidation of the precise targeting mechanism of KRT19 to the plasma membrane or extracellular space warrants further experimental challenges, our data indicate that HER2-induced upregulation and subcellular reorganization of KRT19 and subsequent stabilization of HER2, might be responsible for HER2-driven phenotypic changes in cancer cells. We also provide the first evidence that targeting KRT19 by KRT19 antibody could be a novel therapeutic approach for HER2-positive cancer cells, as well as Trastzumab-resistant JIMT-1 cells. 36 However, it must be noted that complete silencing of KRT19 by shRNA leads to upregulation of cell proliferation by an increase in Akt activity via inhibition of Egr-1/PTEN, as we have reported very recently. 37 As indicated in Supplementary Figure 6 , KRT19 exhibited a biphasic effect on cancer cell proliferation. The cell viability was dependent on KRT19/HER2 signaling at higher KRT19 concentration and it turned to be rather dependent on KRT19/Egr-1 signaling at very low/knockout levels of KRT19.
In conclusion, our studies improve the understanding of HER2-downstream signaling events in cancer cells by demonstrating that HER2-downstream KRT19 could in turn stabilize HER2. Although the usage of KRT19 as a therapeutic target of HER2-positive breast cancer should be carefully considered because of the reason discussed above, our report has implications on using KRT19 as a new therapeutic target against HER2-positve breast cancers.
Materials and Methods
Quantitative mass spectrometry analyses using LC-MS/MS. MCF-7 vec and MCF-7 HER2 cells were prepared as described (Kurokawa et al 38 ). MCF-7 vec and MCF-7 HER2 membrane fractions were prepared by centrifugation of cell lysates at 100 000 × g in a lysis buffer without detergent. The pellets were first hydrolyzed at aspartic acid using ChemDigest TM (http://www.novacelltech.com). The resulting hydrolysate was digested with trypsin and subjected to chromatographic separation by off-line C18 HPLC and analyzed by LC-MS/MS. Mass analyses were performed using a nano-LC-MS system, which consisted of an Ultimate HPLC system (Agilent 1100, Santa Clara, CA, USA) and a QSTAR quadrupole-TOF mass spectrometer (Applied Biosystems/ MDS SCIEX, Concord, Ontario, Canada) equipped with a nano-ESI source. For MS/MS analysis, each scan cycle consisting of one full-scan mass spectrum (m/z 400-1500) and three MS/MS events were followed. LC-MS/MS data were searched against a concatenate target-decoy database of UniProt v15.15 using MASCOT software (version 2.2.04; Matrix Science, London, UK). The proteins that showed quantitative changes of more than twofold were selected and listed. To estimate fold-changes of identified proteins between experimental groups, we applied label-free quantitative analyses based on comparison of fragment ion intensities. 39 We got the spectral index (SI) of each protein, which is the cumulative fragment ion intensity for each significantly identified peptide that gives rise to a protein and was normalized (SIN) by dividing the total SI for all identified proteins (SIT). Log2 ratios of normalized SI, Log2 (SIN_HER2/ SIN_vec) were calculated and used as quantitative index. To avoid taking logarithm on zero's, we set the SI as 0.135 that is the 5th percentile value of SI if no peptide was identified in an experimental group.
Cells lines, kinase inhibitors and antibodies. MCF-7 vec, MCF-7 HER2, BT-474, MDA-MB-231, MDA-MB-468, T47D, SKBR-3, JIMT-1 and KPL-4 human breast cancer cells and 293T human kidney cells were maintained in DMEM or RPMI-1640 (HyClone, Logan, UT, USA) supplemented with 10% fetal bovine serum (FBS), 100 U/ml penicillin, and 100 mg/ml streptomycin. KRT19 knockdown cells were generated by transfection with a KRT19 shRNA (Santa Cruz, Santa Cruz, CA, USA) by Lipofectamine 2000 transfection reagent (Invitrogen, Carlsbad, CA, USA). The following kinase inhibitors were used: U0126, LY294002, Wortmannin, Akt inhibitor #8 and SB203580 (Calbiochem, Darmstadt, Germany); ZD1839 (Biaffin GmbH & Co., Kassel, Germany). The following antibodies were used: His, Ubiquitin, KRT1/10 and AQP4 antibodies (Santa Cruz); p-ERK, ERK, p-p38 MAPK, p38 MAPK, Actin, HA, p-HER2, p-Akt and Akt antibodies (Cell Signaling, Beverly, MA USA); KRT19 antibody (Chemicon, Billerica, MA, USA and Santa Cruz); KRT9 antibody (Abcam, Cambridge, MA, USA); KRT18 antibody (Calbiochem); HER2 (ERBB2/neu) antibody (Lab Vision, Fremont, CA, USA); phosphotyrosine antibody (Upstate, Lake Placid, NY, USA); anti-rabbit IgG-Oregon Green (Molecular Probes, Eugene, OR, USA); anti-mouse IgG-Cy3 (Zymed, San Francisco, CA, USA) and anti-Mouse IgG-PE antibody (Abcam).
Plasmids and site-directed mutagenesis. KRT-WT, HER2-WT, HER2-CA and HER2-KD were purchased from Addgene (Cambridge, MA, USA). KRT19-S10A, and KRT19-S35A were provided by Dr. Omary (Stanford University). The pK19-1970-LucReporter was a gift from Dr. Rustgi (University of Pennsylvania). ERK1-WT, ERK2-WT, p38 MAPK-WT and p38 MAPK-KD were donated by Dr. Su-Jae Lee (Hanyang University). HA-Akt1-CA, HA-Akt1-KD, MEK1-CA and MEK2 were described previously. 40, 41 Using the KRT19-S35A construct as a backbone, KRT19-S10A S35A was produced using a Quickchange kit (Stratagene, San Diego, CA, USA) with the following mutagenic primers: Fwd, 5′-GCTATCGCC AGTCGGCGGCCACGTCGTCCTTC-3′, and Rev, 5′-GAAGGACGACGTGGCCGC CGACTGGCGATAGC-3′. Using the HER2-WT construct as a backbone, HER2-truncated mutant constructs were produced with the following primers, HER2-FLMyc: Fwd, 5′-cgtaagcttATGGAGCTGGCGG-3′, and Rev, 5′-cgttctagaTCACACTG GCACGT-3′ (1 to 3768); HER2-ECD-Myc: Fwd, 5′-cgtaagcttATGGAGCTGGCG G-3′, and Rev, 5′-cgttctagaGGACGTCAGAGGGC-3′ (1 to 1959); HER2-ICD-Myc: Fwd, 5′-cgtaagcttATCATCTCTGCGGTG-3′, and Rev, 5′-cgttctagaTCACACTGG CACGT-3′ (1960-3768). Hind III and XbaI restriction sites are indicated by lowercase letters. The amplified PCR products were ligated into the pCDNA3.1-myc-His B vector (Invitrogen).
Cell fractionation. PBS-washed cells were pelleted by centrifugation, and cells were broken using a 1-ml syringe (26 GX size) in lysis buffer without detergent, after which the supernatants were pelleted by ultracentrifugation for 1 h at 100 000 × g at 4°C. After centrifugation, the supernatant was used as the cytosolic fraction and the pellet was resuspended in lysis buffer for use as the membrane fraction.
Reverse transcriptase-PCR (RT-PCR).
Expression of transcripts were assessed using the following primers, human KRT19: 42 Fwd 5′-GCACTA CAGCCACTACTACACGA-3′, Rev 5′-CTCATGCGCAGAGCCTGTT-3′, HER2: Fwd 5′-AACTGCACCCACTCCTGTGT-3′, Rev 5′-TGATGAGGATCCCAAAGACC-3′. Quantification of actin expression was performed as an internal control using an RT-PCR primer and control set (Invitrogen). Expression of mouse KRT19 was assessed using the following primers: Fwd 5′-TGCTGAAGCCACCTACCTTG-3′, Rev 5′-ATACTCCTGGTTCTGGCGCT-3′, and mouse actin primers: Fwd 5′-TTCT TTGCTCCTTCGTTGCCG-3′, Rev 5′-TGGATGGCTACGTACATGGCTGGG-3′. Western blot analyses, Immunoprecipitation, Immunofluorescence staining and Immunohistochemistry. For western blot analyses, cells were lysed in a lysis buffer containing 50 mM Tris, pH 8.0, 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 50 mM NaF, 1 mM Na3VO4 and protease inhibitor cocktail (Roche, Basel, Switzerland). For KRT western blots, TrisTriton buffer containing 10 mM Tris, pH 7.4, 100 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100, 10% glycerol, 0.1% SDS, 0.5% deoxycholate (suggested for cytoskeletal proteins by Abcam) was used as a lysis buffer. Samples were separated on SDS-PAGE gels and transferred to nitrocellulose membranes (Whatman, Little Chalfont, UK). After blocking with 5% skim milk in TBST, membranes were incubated with appropriate primary antibodies overnight, followed by 2 h incubation with HRP-conjugated secondary antibodies. Protein bands were visualized with WEST ZOL plus System (iNtRON, Seongnam, Korea). For Immunoprecipitation, cell lysates (1 mg) were precleared by adding 30 μl protein A sepharose (Invitrogen) for 2 h at 4°C. After centrifugation at 1000 × g, the supernatant was incubated with either primary antibodies or normal rabbit/mouse immunoglobin G (IgG) overnight at 4°C. Protein A or G Sepharose (30 μl) was added and incubated for 3 h at 4°C. After centrifugation, the pellet was washed three times with cell lysis buffer. Immunoprecipitated proteins were resolved on a 10% SDS-PAGE and subsequently analyzed by western blot. For immunofluorescence staining, cells were washed with PBS, fixed with 4% paraformaldehyde and permeabilized with 0.1% Triton X-100 for 15 min. Fixed samples were blocked with 3% skim milk in PBS for 1 h, followed by incubation with primary antibody diluted in 1% skim milk in PBS for 1h. After washing with PBS the samples were treated with the anti-mouse IgG-Cy3 or anti-rabbit IgG-Oregon Green (Molecular Probes). For DNA staining, samples were incubated with Hoechst 33342 (1 μg/ml) for an additional 10 min. Immunofluorescence was monitored with an Olympus (Tokyo, Japan) upright fluorescence microscope (BX50F) and an Olympus laser scanning confocal microscope (IX2-ILL100). For cell-surface immunofluorescence staining, cells were prepared according to the immunofluorescence staining procedure described above with exception that the permeabilization step was deleted. 43 For immunohistochemistry, mouse mammary gland tissues were fixed in Bouin's solution (Sigma, St. Louis, MO, USA). Tissues were dehydrated, washed in 70% ethanol and embedded in paraffin. Five-μm-thick paraffin sections were then mounted on poly-L-lysine-coated slides and incubated in a dry oven at 60°C for 1 h followed by deparaffinization in xylene. The slides were then rehydrated in 100, 90, 80 and 70% ethanol for 5 min each twice. The slides were incubated with primary antibodies in PBS with 5% FBS in a humidified chamber overnight. The slides were incubated for 30 min with a biotin-conjugated secondary antibody (Vector Laboratories, Orton Southgate, UK). The avidin-biotin complex (ABC) reaction was generated according to the manufacturer's protocol. Sections were counterstained with Mayer's hematoxylin (Sigma).
Proliferation assay. For 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assays, cells were seeded in 96-well culture plates at 5 × 10 3 cells/well, exposed to indicated antibodies and incubated for 72 h. Cell viability was assessed by adding 20 μl of 10 mg/ml MTT (Sigma) to 100 μl of culture medium, and incubating for 3h at 37°C in a CO 2 incubator. The medium was removed, formazan was dissolved in DMSO (Sigma), and the optical density was measured at 590 nm using a Multiskan EX (Thermo, Waltham, MA, USA).
In vitro kinase assay. GST expression plasmids expressing were transformed into E. coli BL21 (DE3). Growth of the E. coli was then induced by addition of 1 mM isopropyl 1-thio-β-D-galactopyranoside, and after 4 h the cultures were collected. Cells were then lysed with a sonicator. Supernatants were loaded onto a glutathione Sepharose 4B column (GE Healthcare, Piscataway, NJ, USA), and bound GSTtagged proteins were eluted in elution buffer (50 mM Tris-HCl pH 9.5, 10 mM reduced glutathione). 293T cells seeded at the density of 1 × 10 6 total cells per 100-mm dish were transfected with 10 μg of HA-Akt and collected 48 h after transfection. Next, a total of 1 mg of whole-cell lysate was incubated with HA-antibody and subsequently treated with protein A-Sepharose CL-4B. The resulting immunocomplexes were incubated with 1.5 μg of pre-purified GST-KRT19 in 15 μl kinase reaction buffer (25 mM Tris-HCl (pH 7.5), 5 mM β-glycerophosphate, 0.1 mM sodium orthovanadate, 2 mM dithiothreitol, 200 μM ATP, 10 mM magnesium chloride) and 10 μCi [γ32P] ATP (GE Healthcare) for 30 min at RT. Samples containing 32P-labeled proteins were analyzed by SDS-PAGE and subsequent autoradiography.
Cycloheximide-decay assay. At 48 h post transfection in 293T, 20 μg/ml cycloheximide (Sigma) was added to block further protein synthesis. MCF-7 cells were treated with 100 μg/ml cycloheximide. Cells were collected at each of the indicated time points and subjected to western blot analysis.
Ubiquitination assay. We transfected 293T cells with a His-ubiquitin expression construct with the indicated plasmids. At 36 h post transfection, cells were treated with the proteosomal inhibitor MG132, 10 μM for 8 h. Cells were then collected and lysed. The supernatant was incubated with 4 μg of His antibody overnight at 4°C. Protein A sepharose (30 μl) was then added and incubated for 4 h at 4°C. After centrifugation at 1000 × g, the pellet was washed three times with lysis buffer. The immunoprecipitated proteins were resolved by SDS-PAGE and subjected to western blot analysis.
Dual luciferase assays. MCF-7 cells in 12-well plates were transfected with 0.2 μg of reporter constructs, pK19-1970-LucReporter, 20 and 0.002 μg of pCMV-Rl as an internal control by using Lipofectamine 2000 (Invitrogen). At 48 h post transfection, dual luciferase assays were performed according to manufacturer's protocol (Promega, Madison, WI, USA). 293T cells were transfected with 1 μg total DNA containing 500 ng of pK19-1970-LucReporter and 0.002 μg of pCMV-Rl constructs by calcium phosphate transfection method.
In vivo labeling. 293T cells were transfected each with 4 μg HA-Akt1-CA and KRT19, and labeled with 500 μCi/mL of [32P] orthophosphate for 18 h in phosphatefree DMEM containing 10% dialyzed FBS. Total cell lysates (1 mg) were precleared by adding 30 μl protein A sepharose (Invitrogen) for 2 h at 4°C. After centrifugation at 1000 × g, the supernatant was incubated with 4 μg of KRT19 antibody overnight at 4°C. Protein A sepharose (30 μl) was then added and incubated for 4 h at 4°C. After centrifugation at 1000 × g, the pellet was washed three times with lysis buffer. Finally, the immunoprecipitated proteins were resolved by SDS-PAGE and subsequent autoradiography.
Cell surface protein biotinylation assay. Cell surface protein biotinylation assay was performed according to Wu et al. 44 In brief, 80~90% confluence cells in 100-mm dishes were washed twice with ice-cold PBS and incubated for a further 15 min in ice-cold PBS. Biotinylation was performed by incubating cells in PBS containing 0.5 mg/ml of NHS-SS-Biotin (Thermo) for 30 min at 4°C. To determine cell-surface level of KRT19, labeled cells were lysed, precipitated with streptavidin-conjugated agarose beads (Invitrogen), and subjected to western blotting with KRT19 antibody. For negative control of non-specific labeling of internal proteins, biotin-labeled cells were washed by PBS twice, then washed by glutathione (GSH) (Sigma).
KRT19 and mouse normal IgG antibodies. We purchased a custombuilt hybridoma cells for mass production of monoclonal KRT19 antibodies from Abby mart Biomedical Co. Ltd. Shanghai (Shanghai, China). Mouse myeloma cells, TIB-9 were purchased from ATCC (Manassas, VA, USA). Antibody production was performed according to Yokoyama et al. 45 In brief, at least 6-week-old BALB/C mice were i.p. injected pristine (Sigma). After a week, mice were inoculated with 1 × 10 6 hybridoma and cells suspended in incomplete Freund's adjuvant (Sigma). Ascites fluid was collected using 18-gauge needles. Antibodies were purified by Montage antibody purification kit (Millipore, Billerica, MA, USA) and screened for endotoxin test.
Tumor growth model and antitumor activity of KRT19 antibody in vivo. Eight-week-old BALB/C nude mice were purchased from ORIENT BIO Inc (Seongnam, Korea). The mice were cared for and used in compliance with institutional guidelines. The mice were given a single s.c. injection of 5 × 10 6 KPL-4 cells suspended in PBS. Tumors were allowed to grow until they reached a diameter of 3-6 mm (day 0). The mice were then randomly divided into different treatment groups. Trastzumab (Roche), KRT19 antibody and mouse nomal IgG were i.p. injected at a dose of 20 mg/kg for every 3 days. Tumor volumes in mm 3 was calculated by the formula: volume = (width) 2 × length/2.
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